162 related articles for article (PubMed ID: 19667283)
1. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
[TBL] [Abstract][Full Text] [Related]
2. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
[TBL] [Abstract][Full Text] [Related]
4. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
5. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
6. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Gazzard B; Pozniak A
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1376-84. PubMed ID: 15483467
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Cotton M; Cassim H; Pavía-Ruz N; Garges HP; Perger T; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Sievers J; Cheng K
Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
[TBL] [Abstract][Full Text] [Related]
8. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
13. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
18. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
van der Lee MJ; Blenke AA; Rongen GA; Verwey-van Wissen CP; Koopmans PP; Pharo C; Burger DM
Antimicrob Agents Chemother; 2007 Nov; 51(11):4098-104. PubMed ID: 17846135
[TBL] [Abstract][Full Text] [Related]
19. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
